Antonie van Leeuwenhoek

, Volume 52, Issue 3, pp 219–220 | Cite as

Group A meningococcal polysaccharide vaccine

What was learned from its use in Finland in 1973–1975 (A review)
  • P. H. Mäkelä


Polysaccharide Polysaccharide Vaccine Meningococcal Polysaccharide Meningococcal Polysaccharide Vaccine 


  1. KäyhtyH., KarankoV., PeltolaH., SarnaS. & MäkeläP. H. (1980) Serum antibodies to capsular polysaccharide vaccine of group ANeisseria meningtidis followed for three years in infants and children. J. Infect. Dis. 142: 861–868Google Scholar
  2. KäyhtyH., JousimiesH., PeltolaH. & MäkeläP. H. (1981) Antibody response to capsular polysaccharides of groups A and CNeisseria meningitidis andHaemophilus influenzae type b during bacteremic disease. J. Infect. Dis. 143: 32–41Google Scholar
  3. KuronenT., PeltolaH., NorsT., HaqueN. & MäkeläP. H. (1977) Adverse reactions and endotoxin content of polysaccharide vaccines. Develop. biol. Standard 34: 117–125Google Scholar
  4. Mäkelä, P. H., Käyhty, H., Weckström, P., Sivonen, A. & Renkonen, O.-V. (1975). Effect of group A meningococcal vaccine in army recruits in Finland. Lancet ii: 883–886Google Scholar
  5. PeltolaH., MäkeläP. H., KäyhtyH., JousimiesH., HervaE., HällströmK., SivonenA., RenkonenO.-V., PettayO., KarankoV., AhvonenP. & SarnaS. (1977) Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N. Engl. J. Med. 297: 686–691Google Scholar

Copyright information

© Martinus Nijhoff Publishers 1986

Authors and Affiliations

  • P. H. Mäkelä
    • 1
  1. 1.National Public Health InstituteHelsinkiFinland

Personalised recommendations